Missed the bullseye, not the board
Delta-Fly Pharma’s lead acute myeloid leukemia drug, radgocitabine (DFP-10917), just took a swing at phase III and didn’t clear the main bar: the primary endpoint was missed. That’s the kind of sentence that usually makes biotech traders reach for the coffee and the aspirin.
But the company isn’t folding the tent
Instead of taping up a “game over” sign, Delta-Fly says it’s still in talks with the FDA about a possible NDA path. The company is leaning on earlier-stage efficacy signals and some emerging combination data — basically saying, “Yes, the big readout was a miss, but check out the rest of the evidence folder.”
Why investors should keep watching
This is the biotech version of overtime. A phase III miss is a real setback, no sugarcoating it, but if management can convince regulators that the total package still supports a conditional approval route, the market may reprice the stock around survival odds instead of pure failure.
What matters next:
- Whether FDA conversations stay alive
- How convincing the earlier-stage data look in hindsight
- Whether combo results can help patch the hole left by the missed endpoint
Big picture: in biotech, the difference between “dead on arrival” and “maybe not dead yet” can be the whole trade.